Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
about
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaPentostatin in chronic lymphocytic leukemiaAn update on the management of chronic lymphocytic leukaemia.Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasmsA Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioThe spectrum of use of rituximab in chronic lymphocytic leukemiaThe pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in miceChronic lymphocytic leukemia: treatment options for patients with refractory disease.Pentostatin and purine analogs for indolent lymphoid malignancies.Recent advances in chronic lymphocytic leukemia.Emerging therapy for chronic lymphocytic leukaemia.Personalized medicine in CLL: current status and future perspectives.Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.Changing paradigms in the treatment of chronic lymphocytic leukemia.A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options.Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies.Treatment of relapsed or refractory chronic lymphocytic leukemia.The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy.The addition of rituximab to fludarabine and cyclophosphamide improves progression-free survival in patients with previously treated chronic lymphocytic leukemia.Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488.
P2860
Q24681296-ACFDCE51-0432-44BF-9446-D53C563DE27FQ28291531-9413A724-2529-4B98-9E07-BE91EC560734Q30341946-0B2DD1DA-1036-4530-9228-8FC175B9E360Q33386506-3DB10251-FBB7-4901-8EB6-197398F9E554Q33397239-5FC860F7-3C84-4C31-8A19-62B91264A738Q33406478-DB1A9131-1580-4536-AC89-45330A8BAACDQ34202277-58BAF6E4-32D9-4B3B-B6D1-1DE16CFF1EFAQ34510030-86A4E95C-D2A3-4458-ABE7-9ABFC23F25ADQ34700443-302C117D-7E11-4425-AAFE-131C4530D3B2Q35023967-B173EEC6-42AC-4C0A-B2E9-F92D412E2230Q35070412-B28D8014-DD38-477A-973A-DB10B08C1100Q35382716-AC510A32-0E4F-4EB7-9A1E-D9BCCD9B9102Q36430721-64663E39-701F-496A-AF5D-2DBB1DBF5FACQ36523498-F11EB938-7BF3-413F-9D10-59FBEA4B9534Q36981738-32C4F394-7FA7-4A34-8C5B-3D1C484773E1Q37412148-5F0DBFBC-F129-492D-88CE-806441E9AEF1Q37424784-0102008D-188B-4B33-B1ED-F5153EF37381Q37613316-E57D88C7-74F2-46F8-9213-FD73312D5CA1Q37662198-1581E779-6A82-4F76-939A-CB6EFF1A9528Q37694617-43571512-6F85-418F-8FD4-0BFC0FB03449Q37764869-6FA55FC0-AD22-44A8-A188-AFD59503C43AQ37799820-C0E4FE80-2A50-4A55-93D1-ADE2CD2DB5E9Q37963498-5E8B9462-4A91-4DA2-8571-13164CBCFAF8Q37964916-1660FA2E-F7B8-41A4-B04E-2298BE390363Q38126946-F269736D-FC4D-4CD2-B24C-119FFDC3492BQ42920639-E4C39B8E-C7A1-463C-916A-329AEBAFF8C4Q44827791-D20CC2FD-7DDF-4E04-8EFD-5AFB791F23A2
P2860
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pentostatin and cyclophosphami ...... chronic lymphocytic leukemia.
@ast
Pentostatin and cyclophosphami ...... chronic lymphocytic leukemia.
@en
type
label
Pentostatin and cyclophosphami ...... chronic lymphocytic leukemia.
@ast
Pentostatin and cyclophosphami ...... chronic lymphocytic leukemia.
@en
prefLabel
Pentostatin and cyclophosphami ...... chronic lymphocytic leukemia.
@ast
Pentostatin and cyclophosphami ...... chronic lymphocytic leukemia.
@en
P2093
P356
P1476
Pentostatin and cyclophosphami ...... chronic lymphocytic leukemia.
@en
P2093
David A Scheinberg
Denise Horgan
Joseph G Jurcic
Mark A Weiss
Nicole Lamanna
Stanley R Frankel
Steven E Kossman
Timothy B Aliff
P304
P356
10.1200/JCO.2003.08.100
P407
P577
2003-04-01T00:00:00Z